Bryan D. Marks
Impact in
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
-
- Computational Drug Discovery Methods
Papers in
-
- bioluminescence and chemiluminescence research 2
- Oncology 6
- Drug Transport and Resistance Mechanisms 3
- HER2/EGFR in Cancer Research 2
- Co-authors
- Olga V. Trubetskoy (5 shared papers)William J. Frazee (4 shared papers)Steven M. Riddle (5 shared papers)Kurt W. Vogel (5 shared papers)Mary Szatkowski Ozers (4 shared papers)Connie S. Lebakken (3 shared papers)Upinder Singh (2 shared papers)Mohammed Saleh Shekhani (3 shared papers)
- Journals
- Assay and Drug Development Technologies (4 papers)SLAS DISCOVERY (4 papers)Journal of Huntington s Disease (1 paper)Biochemistry (1 paper)The AAPS Journal (1 paper)
- Partner nations
- United StatesNorwayUnited Kingdom
In The Last Decade
Bryan D. Marks
16 papers receiving 412 citations
Peers
Comparison fields: 5 of 75
- Pharmacology 138
- Computational Theory and Mathematics 60
- Molecular Biology 244
- Oncology 83
- Endocrinology, Diabetes and Metabolism 45
Countries citing papers authored by Bryan D. Marks
This map shows the geographic impact of Bryan D. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan D. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan D. Marks more than expected).
Fields of papers citing papers by Bryan D. Marks
This network shows the impact of papers produced by Bryan D. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan D. Marks. The network helps show where Bryan D. Marks may publish in the future.
Co-authors
The 25 scholars most cited alongside Bryan D. Marks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 68 | |
| 2 | 2005 | 65 | |
| 3 | 2009 | 45 | |
| 4 | 2006 | 45 | |
| 5 | 2005 | 41 | |
| 6 | 2008 | 37 | |
| 7 | 2002 | 30 | |
| 8 | 2013 | 23 | |
| 9 | 2005 | 16 | |
| 10 | 2003 | 16 | |
| 11 | 2011 | 16 | |
| 12 | 2004 | 15 | |
| 13 | 2006 | 14 | |
| 14 | 2008 | 9 | |
| 15 | 2023 | 1 | |
| 16 | 2011 | 1 | |
| 17 | 2024 | 0 |
About Bryan D. Marks
Bryan D. Marks is a scholar working on Molecular Biology, Oncology, Pharmacology, Computational Theory and Mathematics and Hematology, having authored 17 papers that have together received 442 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (6 papers), Computational Drug Discovery Methods (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Estrogen and related hormone effects (3 papers), Drug Transport and Resistance Mechanisms (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), bioluminescence and chemiluminescence research (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Pharmacology (138 citations), Computational Theory and Mathematics (60 citations), Molecular Biology (244 citations), Oncology (83 citations) and Endocrinology, Diabetes and Metabolism (45 citations). Bryan D. Marks has collaborated with scholars based in United States, Norway and United Kingdom. Frequent co-authors include Olga V. Trubetskoy, William J. Frazee, Steven M. Riddle, Kurt W. Vogel, Mary Szatkowski Ozers, Connie S. Lebakken, Upinder Singh, Mohammed Saleh Shekhani, Mei‐Fei Yueh and Yi Qin Gao. Their work appears in journals such as Assay and Drug Development Technologies, SLAS DISCOVERY, Journal of Huntington s Disease, Biochemistry and The AAPS Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.